IONS

Ionis Pharmaceuticals, Inc. [IONS] Stock Forecast

Q: What is Ionis Pharmaceuticals, Inc. stock symbol ?

Ionis Pharmaceuticals, Inc. is a US stock, located in Carlsbad of Ca and trading under the symbol IONS

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

IONS Stock Summary

Earnings have grown 34.18% per last year.

Has a high level of debt. Debt-to-Equity ratio of 3.76 is considered high.

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 years (Yearly statements)

IONS has less than 1 year of cash runway

Top 10 Correlated ETFs

IONS

Top 10 Correlated Stocks

IONS

In the News

IONS Financial details

Company Rating

Neutral

Market Cap

6.08B

Income

-365.26M

Revenue

787.51M

Book val./share

2.69

Cash/share

16.19

Dividend

Dividend %

Employees

927

Optionable

Shortable

Yes

Earnings

01 May 2024

P/E

-17.04

Forward P/E

PEG

-4.95

P/S

P/B

16.09

P/C

2.5

P/FCF

-18.82

Quick Ratio

5.42

Current Ratio

5.9

Debt / Equity

3.76

LT Debt / Equity

3.62

EPS (TTM)

-2.55

EPS next Y

EPS next Q

EPS this Y

34.74%

EPS next Y

EPS next 5Y

EPS last 5Y

NAN%

Revenue last 5Y

-6.85%

Revenue Q/Q

125.35%

EPS Q/Q

-93.76%

SMA20

-4.65%

SMA50

-18%

SMA100

-16.33%

Inst Own

71.08%

Inst Trans

0.76%

ROA

-12%

ROE

-90%

ROC

-0.14%

Gross Margin

99%

Oper. Margin

-45%

Profit Margin

-46%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

34.32-54.44

52W High

-25.19%

52W Low

+18.82%

RSI

Rel Volume

0.37

Avg Volume

1.17M

Volume

426.71K

Perf Week

-4.94%

Perf Month

-8.16%

Perf Quarter

-8.29%

Perf Half Y

-16.72%

Beta

0.402

Volatility

0.46%, 1.03%

Prev Close

-1%

Price

40.4

Change

-1.46%

IONS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	8.02	5.22	5.74	4.14	5.5
Net income per share	2.1	-3.49	-0.21	-1.9	-2.56
Operating cash flow per share	2.47	0.26	0.22	-1.93	-2.15
Free cash flow per share	2.21	-0.04	0.09	-2.08	-2.34
Cash per share	30.83	24.26	23.83	26.07	16.28
Book value per share	10.51	6.04	5.47	4.04	2.7
Tangible book value per share	11.85	5.84	5.27	4.04	2.7
Share holders equity per share	10.51	6.04	5.47	4.04	2.7
Interest debt per share	5.44	7.79	8.29	9.59	10.68
Market cap	8.46B	7.89B	4.29B	5.36B	7.24B
Enterprise value	6.67B	6.75B	3.34B	4.72B	8.3B
P/E ratio	28.77	-16.21	-147.97	-19.84	-19.78
Price to sales ratio	7.53	10.83	5.3	9.13	9.2
POCF ratio	24.46	219.93	139.33	-19.53	-23.56
PFCF ratio	27.33	-1.53K	332.71	-18.19	-21.59
P/B Ratio	5.75	9.36	5.56	9.35	18.73
PTB ratio	5.75	9.36	5.56	9.35	18.73
EV to sales	5.94	9.26	4.12	8.03	10.54
Enterprise value over EBITDA	18.22	-39.25	-158.92	-8.41	-25.7
EV to operating cash flow	19.29	188.08	108.36	-17.19	-26.99
EV to free cash flow	21.55	-1.31K	258.74	-16.01	-24.73
Earnings yield	0.03	-0.06	-0.01	-0.05	-0.05
Free cash flow yield	0.04	0	0	-0.05	-0.05
Debt to equity	0.48	1.24	1.51	2.36	3.76
Debt to assets	0.22	0.44	0.45	0.53	0.49
Net debt to EBITDA	-4.89	6.65	45.43	1.14	-3.27
Current ratio	9.97	7.34	9.73	7.06	5.9
Interest coverage	7.47	-3.82	-6.98	-50.6	-4.68
Income quality	1.14	-0.07	-1.08	1.02	0.84
Dividend Yield	0.02	0	0	0	0
Payout ratio	0.56	0	-0.58	-0.04	0
Sales general and administrative to revenue	0.26	0.49	0.21	0.26	0.3
Research and developement to revenue	0.41	0.73	0.79	1.42	1.14
Intangibles to total assets	0.01	0.01	0.01	0	0
Capex to operating cash flow	-0.1	-1.14	-0.58	0.07	0.09
Capex to revenue	-0.03	-0.06	-0.02	-0.03	-0.04
Capex to depreciation	-2.27	-2.39	-0.92	-0.91	-1.25
Stock based compensation to revenue	0.13	0.32	0.15	0.17	0.13
Graham number	22.28	21.77	5.03	13.15	12.47
ROIC	0.15	-0.02	-0.01	-0.2	-0.19
Return on tangible assets	0.09	-0.21	-0.01	-0.11	-0.12
Graham Net	20.18	13.66	11.2	12.46	-1.29
Working capital	2.45B	1.84B	2.1B	1.89B	2.19B
Tangible asset value	1.66B	815.06M	743M	573M	386.69M
Net current asset value	1.17B	583M	505M	242M	38.47M
Invested capital	0.48	1.24	1.51	2.36	3.76
Average receivables	37.88M	69.5M	69M	44M	61.89M
Average payables	22.36M	16.63M	14.55M	14.91M	21.97M
Average inventory	13.38M	20.07M	23.39M	23.42M	25.23M
Days sales outstanding	20.48	38.05	27.94	16.17	45.31
Days payables outstanding	1.47K	523.14	395	467.23	1.04K
Days of inventory on hand	1.66K	668.1	823.11	574.43	1.14K
Receivables turnover	17.83	9.59	13.06	22.58	8.06
Payables turnover	0.25	0.7	0.92	0.78	0.35
Inventory turnover	0.22	0.55	0.44	0.64	0.32
ROE	0.2	-0.58	-0.04	-0.47	-0.95
Capex per share	-0.26	-0.29	-0.13	-0.14	-0.2

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	1.07	0.92	1.31	1	2.25
Net income per share	-0.37	-0.87	-0.59	-1.03	-0.06
Operating cash flow per share	-1.41	-0.94	-0.68	-0.76	0.23
Free cash flow per share	-1.45	-1.02	-0.77	-0.78	0.23
Cash per share	26.04	16.44	16.67	15.6	16.19
Book value per share	4.04	3.41	2.99	2.2	2.69
Tangible book value per share	4.04	3.41	2.99	2.2	2.69
Share holders equity per share	4.04	3.41	2.99	2.2	2.69
Interest debt per share	9.57	9.7	10.6	10.14	10.24
Market cap	5.36B	5.1B	5.87B	6.5B	7.28B
Enterprise value	4.72B	6.15B	6.92B	7.55B	8.34B
P/E ratio	-25.79	-10.28	-17.27	-11.06	-196.61
Price to sales ratio	35.29	38.94	31.23	45.14	22.45
POCF ratio	-26.79	-38.07	-60.3	-59.63	221.66
PFCF ratio	-26.14	-35.01	-53.16	-57.91	216.27
P/B Ratio	9.36	10.48	13.72	20.64	18.84
PTB ratio	9.36	10.48	13.72	20.64	18.84
EV to sales	31.06	46.97	36.81	52.45	25.7
Enterprise value over EBITDA	-13.19	-63.44	-117.3	-61.4	-4.99K
EV to operating cash flow	-23.58	-45.92	-71.08	-69.28	253.74
EV to free cash flow	-23.01	-42.23	-62.67	-67.28	247.57
Earnings yield	-0.01	-0.02	-0.01	-0.02	0
Free cash flow yield	-0.04	-0.03	-0.02	-0.02	0
Debt to equity	2.36	2.81	3.5	4.56	3.76
Debt to assets	0.53	0.47	0.5	0.49	0.49
Net debt to EBITDA	1.79	-10.85	-17.78	-8.55	-631.3
Current ratio	7.06	3.33	3.28	2.82	5.9
Interest coverage	-36.35	-7.13	-5.06	-7.94	-0.29
Income quality	3.82	1.08	1.14	0.74	-3.55
Dividend Yield	0	0	0	0	0
Payout ratio	-0.01	0	0	0	0
Sales general and administrative to revenue	0.67	0.35	0.25	0.49	0.22
Research and developement to revenue	2.03	1.51	1.22	1.49	0.79
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.03	0.09	0.13	0.03	0.02
Capex to revenue	-0.03	-0.09	-0.07	-0.02	0
Capex to depreciation	-0.71	-2.09	-2.3	-0.58	0.15
Stock based compensation to revenue	0.17	0.21	0.14	0.18	0.08
Graham number	5.77	8.17	6.32	7.12	1.97
ROIC	-0.12	-0.06	-0.05	-0.08	-0.01
Return on tangible assets	-0.02	-0.04	-0.03	-0.05	0
Graham Net	12.44	-0.21	-0.87	-1.84	-1.28
Working capital	1.89B	1.78B	1.82B	1.67B	2.19B
Tangible asset value	573M	487M	428M	315M	386.69M
Net current asset value	242M	145M	73M	-34M	38.47M
Invested capital	2.36	2.81	3.5	4.56	3.76
Average receivables	16.32M	20M	21M	85M	119.89M
Average payables	19.23M	14.21M	17.26M	14.82M	15.82M
Average inventory	21.34M	22.12M	23.87M	25.59M	27.03M
Days sales outstanding	15.39	9.62	13.4	88.75	27.12
Days payables outstanding	403.22	944.91	720.63	252.68	765
Days of inventory on hand	495.74	2K	766.14	1.15K	835.48
Receivables turnover	5.85	9.36	6.71	1.01	3.32
Payables turnover	0.22	0.1	0.12	0.36	0.12
Inventory turnover	0.18	0.05	0.12	0.08	0.11
ROE	-0.09	-0.25	-0.2	-0.47	-0.02
Capex per share	-0.04	-0.08	-0.09	-0.02	0.01

IONS Frequently Asked Questions

What is Ionis Pharmaceuticals, Inc. stock symbol ?

Ionis Pharmaceuticals, Inc. is a US stock , located in Carlsbad of Ca and trading under the symbol IONS

What is Ionis Pharmaceuticals, Inc. stock quote today ?

Ionis Pharmaceuticals, Inc. stock price is $40.4 today.

Is Ionis Pharmaceuticals, Inc. stock public?

Yes, Ionis Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 1.17M
Market Capitalization 6.08B
Employee 927
CEO Dr. Brett P. Monia Ph.D.
Headquarters Carlsbad,CA,US
IPO Date 1991-05-17
Website https://www.ionispharma.com

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.